Recipharm announced the appointment of Greg Behar as chief executive officer. Marc Funk, who successfully led Recipharm into its next phase of growth, will join the board of directors, where he will continue to support the Group. Greg Behar will join Recipharm as CEO for the Group on 1 January 2024.

Greg has had a distinguished career in the healthcare sector, most recently as CEO of Nestle Health Science. Prior to this, Greg held a number of positions within the pharma and biotech industry, including at Novartis and Boehringer Ingelheim. Under Marc's leadership, Recipharm has significantly invested into its operating platform and commercial capabilities making it a global CDMO of choice.

In 2022, Marc oversaw the creation of the Group's Biologics Business Unit, ReciBioPharm, with the acquisitions of ArrantaBio, Vibalogics and GenIbet, as well as the creation of NewBiologix, a venture to develop a novel approach to cell line engineering. Marc will remain on the Board of NewBiologix as well as CEO and Board Member of MarBio, Recipharm's vaccine sterile fill and finish joint venture with the Kingdom of Morocco. This will allow Marc to extend his support to bolster the African continent's capabilities in the production of biological medicines and vaccines, with the ultimate objective of helping the continent to be more self-reliant in the event of future pandemics.